Aptevo Therapeutics Inc APVO
News
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone